Approximately 13 meters below the sea surface, plants are growing in controlled hydroponic systems. The environment is unusual, and it is monitored with care so that every response can be studied.
This is the Aquafarm, the research platform at the center of BioEridan. The scientist who built BioEridan around this broader idea is Jelena Milovanovic, Founder and CEO. Her path runs through ecology, biotechnology, and genetic engineering, and it has arrived at a proposition that is simple to state and demanding to prove: plants under carefully controlled stress may produce compounds that deepen our understanding of cellular aging.
A Curiosity About Natural Systems
Jelena’s story begins with ecology and a fascination with the intelligence of natural systems. She wanted to know how organisms respond to changes in their environment, and her curiosity did not stop at what is visible. It moved down to the biological and molecular level.
That pull led her toward biotechnology and genetic engineering. There she became interested in a specific possibility: that mechanisms observed in nature could be translated into new approaches to human health.
Longevity followed as a natural extension. For her, it has never been simply about living longer. It concerns healthspan, the years of life in which a person remains healthy, functional and biologically resilient.
Her academic work and her entrepreneurial journey gradually converged around that idea. Today, through BioEridan, she explores how plant biotechnology, controlled environmental stress and naturally derived bioactive compounds can contribute to the understanding of cellular aging and longevity.
The temperament behind it is stated plainly. “I am a scientist first, and that continues to shape how I build companies: curiosity creates the hypothesis, but evidence determines where we go next.”
The Idea Behind BioEridan
BioEridan grew out of a question. “What if we could use nature not only as a source of ingredients, but as an active biological laboratory?”
The reasoning rests on how plants behave. Unlike animals, they cannot leave when conditions turn difficult, so they respond biochemically. They alter their metabolism, activate defense pathways, and produce compounds that help them adapt. That capacity became one of the foundations of the company.
The team began by investigating whether controlled environmental conditions, including underwater cultivation and specific biological stressors, could influence the metabolic profile of plants. The hope was that this might lead to interesting bioactive compounds. From that work came the Aquafarm concept.
The long-term objective is precise. Jelena and her team aim to identify and characterize naturally derived compounds with potential relevance to cellular aging, including areas such as telomere biology. Promising candidates would then be subjected to appropriate scientific validation.
More Than a Farm
The Aquafarm is not, in Jelena’s framing, merely an underwater cultivation system. It is designed as a biotechnology research platform.
Within its hydroponic systems, the team studies how specific environmental conditions and stressors, iodine exposure among them, influence plant metabolism and the production of bioactive compounds. At the core lies the concept of biological adaptation. When a plant’s environment changes, it activates complex biochemical pathways, and the team studies those responses, analyzes the shifts in biochemical profiles, and investigates whether the resulting compounds merit further research.
The distinction matters. BioEridan is not simply extracting compounds from conventionally cultivated plants. It is exploring whether controlled environmental conditions can reproducibly influence plant biology and, in turn, the composition of the compounds those plants produce. In that sense, the Aquafarm is a controlled platform for studying and discovering naturally derived bioactive compounds.
Aging Is Not a Single Story
Jelena is direct about the field’s most persistent misconception: that longevity means finding one molecule that lets people live forever. Aging, she says, is far more complex.
She names the processes that interact across a lifetime: telomere dynamics, cellular senescence, mitochondrial function, genomic stability, epigenetic alterations and inflammation, among many others. “No serious scientist should reduce aging to a single mechanism.”
A second misconception concerns the word ‘natural.’ Nature offers extraordinary chemical diversity, she notes, but a natural compound is not automatically effective or scientifically validated. It still needs rigorous characterization and evidence. Her conclusion is that the next generation of longevity biotechnology must move away from exaggerated promises and toward measurable biology.
This is where telomeres enter her own work. They are the protective structures at the ends of chromosomes, and their dynamics are associated with cellular replication and aging. Yet they are only one part of a much larger biological system, which is why BioEridan’s approach follows a defined progression: cultivate, observe, identify, characterize, test, and validate.
The order is deliberate. “We do not want to begin with a marketing claim and search for science to support it.” Biology comes first, and the evidence decides what can ultimately become an ingredient, a technology or a product.
Between the Lab and the Boardroom
Jelena describes her role as unusual because it moves continuously between science and entrepreneurship. One part of her day may involve research strategy and discussions of biological mechanisms. Another may turn to intellectual property, investment, partnerships, product development, or international expansion.
As founder and CEO, her responsibility is to connect these worlds. A scientific discovery, she points out, does not automatically become an innovation. It must be validated, protected, manufactured, financed and regulated before it can be translated into something useful.
Still, the part she remains most passionate about is discovery. She speaks of the extraordinary moment when data shows a scientist something unexpected. “That is where curiosity begins again.”
The company she leads is built around interdisciplinary thinking. Developing biotechnology, she says, requires far more than expertise in one discipline. Research, plant biology, biotechnology, formulation, business development, intellectual property, commercialization and investment all need to communicate with one another.
She wants people who are comfortable challenging assumptions. “I never want hierarchy to become more important than evidence.” The best teams, in her view, are not made of people who think identically. They combine different expertise with a shared standard of scientific rigor and a shared long-term objective.
The Test of Leadership
One of the defining challenges of Jelena’s career was the transition from scientist to founder. She had to learn to communicate a highly unconventional biotechnology concept to investors.
The context added weight. Building a biotech company in the Balkans already means operating outside the world’s largest biotechnology ecosystems, and doing so as a female founder added another dimension to the experience. An innovative idea was not enough. She needed evidence, persistence, financial understanding, and the ability to explain complex science clearly.
The process of securing venture-capital investment became part of that education, but the greater lesson was learning to distinguish useful skepticism, which can make a company and its science stronger, from the kind that simply reflects unfamiliarity with something new. “Leadership taught me to listen to both, but respond to evidence.”
Milestones on the Way
Jelena measures progress by how far BioEridan has traveled from a scientific concept toward an internationally visible biotechnology venture. Several markers stand out.
Securing venture-capital investment was an important validation of the company’s potential and, for her, a personal milestone as a biotech founder from the Balkans. The Aquafarm is another, because it gives the team an environment in which to investigate plant adaptation and bioactive compounds under controlled underwater conditions.
Recognition has also accelerated. The documentary ‘BioEridan: Science Beneath the Surface’ was presented at Christ’s College, University of Cambridge, bringing the company’s story and scientific vision to an international audience. Following its premiere, the BioEridan story received extensive international media attention.
Jelena is careful about what that attention means. Visibility, she says, is meaningful only when it helps advance science. The next milestones must increasingly be measured through research results, validation, intellectual property, partnerships, and the ability to translate discoveries into scalable applications.
From Molecule to Everyday Life
To Jelena, the different arms of her work are expressions of a single philosophy rather than separate businesses. BioEridan represents the research and biotechnology side. Eridan Beauty, her skincare company, explores the intersection of nature, biotechnology, and consumer application.
Beauty interests her for a particular reason. The skin is a living biological system and one of the most visible manifestations of aging. Her interest, however, extends beyond appearance. She wants to understand how discoveries made at the molecular level can eventually become products that people use in everyday life.
That connection has to be built carefully. She insists that the link between research, evidence, and real-world application be preserved through the entire process, from the first observation to the finished product.
What Comes Next
The next phase for BioEridan is defined by three words: validation, scalability and internationalization. The company intends to continue its research, expand the scientific capabilities of the Aquafarm platform, characterize promising bioactive compounds and build partnerships that can accelerate validation and commercialization.
International collaboration is central to that plan. Jelena is clear that biotechnology cannot develop in isolation, and she is interested in relationships with research institutions, laboratories, industry partners, and investors who share the company’s long-term perspective.
Her larger vision is for BioEridan to become a biotechnology platform capable of discovering and developing biologically active ingredients inspired by the adaptive intelligence of nature. She wants a company that originated in Serbia to contribute meaningful science to the global longevity ecosystem.
Her message for the field balances ambition with discipline. “The future of longevity will belong to people who are ambitious enough to ask extraordinary questions but disciplined enough to accept only evidence-based answers.” Jelena sees no reason to fear imagining a future in which people live healthier for longer, but she insists that ambition must never move faster than scientific integrity.
The reference point remains nature, which has spent billions of years developing mechanisms for survival, adaptation and resilience. Biotechnology, she says, offers increasingly sophisticated tools for understanding them. And perhaps, she suggests, some of the most important innovations in human longevity will come from places, organisms and environments we have not yet thought to investigate.
Quotes
